Experience with the use of intravitreal bevacizumab in cases with type I retinopathy of prematurity in a Latin American country.
Arch Soc Esp Oftalmol (Engl Ed)
; 2024 May 18.
Article
en En
| MEDLINE
| ID: mdl-38768850
ABSTRACT
In retinopathy of prematurity (ROP) type I, the use of intravitreal bevacizumab (IVB), which is an inhibitor of endothelial growth factor (VEGF), has become popular despite not being a therapy approved by regulatory agencies. However, IVB has shown positive effects in halting disease progression at lower costs compared to other anti-VEGF therapies (ranibizumab or aflibercept). In this report, we present the experience during the treatment with IVB of 102 Colombian children with ROP type I, with a success rate of 98% (100). Complications occurred in 3.9% (4). Finally, we conclude that a single dose of IVB is an effective therapy for the management of ROP type I, with a lower risk of complications and retreatment.
Texto completo:
1
Bases de datos:
MEDLINE
Idioma:
En
Revista:
Arch Soc Esp Oftalmol (Engl Ed)
Año:
2024
Tipo del documento:
Article
País de afiliación:
Colombia